Preliminary results and a theoretical perspective of co‑treatment using a miR‑93‑5p mimic and aged garlic extract to inhibit the expression of the pro‑inflammatory interleukin‑8 gene
Open Access
- 25 February 2025
- journal article
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 29 (4) , 1-11
Abstract
The coronavirus disease‑19 (COVID‑19) pandemic has been a very significant health issue in the period between 2020 and 2023, forcing research to characterize severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) sequences and to develop novel therapeutic approaches. Interleukin‑6 (IL‑6) and IL‑8 are considered significant therapeutic targets for COVID‑19 and emerging evidence has suggested that microRNAs (miRNAs/miRs) serve a key role in regulating these genes. MiRNAs are short, 19‑25 nucleotides in length, non‑coding RNAs that regulate gene expression at the post‑transcriptional level through the sequence‑selective recognition of the 3'‑untranslated region (3'‑UTR) of the regulated mRNAs, eventually repressing translation, commonly, via mRNA degradation. For example, among several miRNAs involved in the regulation of the COVID‑19 ‘cytokine storm’, miR‑93‑5p can inhibit IL‑8 gene expression by directly targeting the 3'‑UTR of IL‑8 mRNA. In addition, miR‑93‑5p can regulate Toll‑like receptor‑4 (TLR4) and interleukin‑1 receptor‑associated kinase 4 (IRAK4) expression, thus affecting the nuclear factor‑κB (NF‑κB) pathway and the expression of NF‑κB‑regulated genes, such as IL‑6, IL‑1β and other hyper‑expressed genes during the COVID‑19 ‘cytokine storm’. In the present study, the results provided preliminary evidence suggesting that the miR‑93‑5p‑based miRNA therapeutics could be combined with the anti‑inflammatory aged garlic extract (AGE) to more effectively inhibit IL‑8 gene expression. The human bronchial epithelial IB3‑1 cell line was employed as experimental model system. IB3‑1 cells were stimulated with the BNT162b2 COVID‑19 vaccine and transfected with pre‑miR‑93‑5p in the absence or in the presence of AGE, to verify the inhibitory effects on the BNT162b2‑induced expression of the IL‑8 gene. The accumulation of IL‑8 mRNA was assessed by RT‑qPCR; the release of IL‑8 protein was determined by Bio‑Plex assay. In addition, the possible applications of TLR4/NF‑κB inhibitory agents (such as miR‑93‑5p and AGE) for treating human pathologies at a hyperinflammatory state, such as COVID‑19, cystic fibrosis and other respiratory diseases, were summarized.Keywords
This publication has 83 references indexed in Scilit:
- MicroRNAs in NF- B signalingJournal of Molecular Cell Biology, 2011
- Sustained inhibition of IL‐6 and IL‐8 expression by decoy ODN to NF‐κB delivered through respirable large porous particles in LPS‐stimulated cystic fibrosis bronchial cellsThe Journal of Gene Medicine, 2011
- Anti-inflammatory effect of miglustat in bronchial epithelial cellsJournal of Cystic Fibrosis, 2008
- Therapeutic inhibition of CXCR2 by Reparixin attenuates acute lung injury in miceBritish Journal of Pharmacology, 2008
- MicroRNA: basic mechanisms and transcriptional regulatory networks for cell fate determinationCardiovascular Research, 2008
- MicroRNA Detection and Target Prediction: Integration of Computational and Experimental ApproachesDNA and Cell Biology, 2007
- TLR-Induced Inflammation in Cystic Fibrosis and Non-Cystic Fibrosis Airway Epithelial CellsThe Journal of Immunology, 2005
- Toll-Like Receptors in Normal and Cystic Fibrosis Airway Epithelial CellsAmerican Journal of Respiratory Cell and Molecular Biology, 2004
- Specificity of microRNA target selection in translational repressionGenes & Development, 2004
- Toll-like receptor–mediated NF-κB activation: a phylogenetically conserved paradigm in innate immunityJournal of Clinical Investigation, 2001